German-Cortés J, Herrero R, Torroglosa N, Pumarola A, Fischer-Albiol N, Campos-Moreno S, Sabaté S, Alcina A, Mancilla S, García B, Diaz-Riascos V, Martins C, Schwartz S Jr, Ferrer R, Abasolo I, Sánchez-Gomez P, Sarmento B, Rafael D, Andrade F.
Preclinical Evaluation of Polymeric Micelles Identifies Soluplus®-Docetaxel as the Most Effective Candidate in 2D, 3D, and In Vivo Glioblastoma Models.
J Control Release, 2025 May 10;381:113616.
DOI: 10.1016/j.jconrel.2025.113616
IF: 11.50
RESEARCH GROUPS
Clinical Biochemistry, Drug Delivery & Therapy
24
Number of publications
70.83
%
% Q1
16.67
%
% D1
83.33
%
% Leadership
90.00
%
% Female Leadership
3.67
CROWN (2021-2025)
14.36
%
HCP10% (2021-2025)
70.83
%
% Open access
20.83
%
% International Collaboration
4
Highly cited papers / HCP 1% (2021-2025)
2
Publications in high-IF journals with high Altmetric scores
24
Number of Ongoing Projectes (total)
6
International ongoing projects
2
Number of New projects (total)
0
International new projects
0
Number of Active clinical Trials
0
Number of New Clinical Trials
2
Number of Theses
Our scope of action ranges from the analysis of massive data to generate new IA-based disease predictor algorithms to the development of new diagnostic biomarkers (i.e., Kidney) and the evaluation of existing diagnostic PoC devices for telemedicine applications. Our group is pioneering the clinical validation of capillary blood microsampling devices for continuous clinical follow-up in homecare scenarios. We also also focus in the development and preclinical validation of new nanomedicines and ATMPs (e.g., non-viral gene therapy and the delivery of intracellular inhibitors against undruggable molecular targets), including new polymer-based delivery systems, solid lipid nanoparticles, liposomes and stimuli-responsive hydrogels. We also host the Functional Validation and Preclinical Research unit (ISO9001:2015) – ICTS: Nanbiosis, performing preclinical validation studies to advance products to clinical phases.
CORE/MISSIONS
- AI, Data, Imaging & Digital Health
- Innovative & Advanced Therapies
- Rare Diseases
PROGRAMS
TEAM
Group Leader
Roser Ferrer Costa
Principal Investigator (PI)
Simo Schwartz Navarro, Fernanda Raquel Da Silva Andrade, Zamira Vanessa Diaz Riascos, Diana Fernandes de Rafael, Concepció Jacobs Cachá, Joaquin Seras Franzoso
Researchers
José Antonio Arranz Amo, Andrea Caballero Garralda, Clara Carnicer Cáceres, Laura Conesa Milian, Noelia Díaz Troyano, Pablo Gabriel Medina, Maria del Pilar Reimundo Diaz-Fierros, Mireia Salvadó Pau, Yolanda Villena Ortiz, Luz Maria Cruz Carlos, Immaculada Comas Reixach
PhD Students
Diego Baranda Martínez-Abascal, Laura Castellote Bellés, Laura Castillo Ribelles, Maria Fidel Lledò, Julia Germán Cortes, Marina Giralt Arnaiz, Thomas Glynn, Gonzalo González Silva, Marc Miquel Moltó Abad, Vincenzo Montanarella, Clara Ramírez Serra, Verónica Villagrasa Araya, Giacomoluciano Vitelli, Carmen Llorens Cebrià, Jaume Barallat Martínez de Osaba, Celia Monteagudo López, Javier Esparcia Estrela, Maria Magdalena Garcias Ramis, Estibaliz Allo Urzainqui, Lydia Peris Serra, Victor Martin Riera
Lab Technicians
Angels Alcina Mila, Mireia Benito Jimenez, Pilar Bonet Palomares, Víctor García García, Laura García Latorre, Belen Garcia Prats, Sandra Mancilla Zamora, Gerard Ruiz Salinas, Sergio Ruiz Baena, Maria del Carmen Sanchez Valcarcel, Francisco Jesus Torralba Saban
SELECTED PUBLICATIONS
Diaz-Riascos Z, Llaguno M, Lafuente-Gómez N, Luengo Y, Holmes S, Volatron J, Ibarrola O, Mancilla S, Sarno F, Aguirre J, Razafindrakoto S, Southern P, Teran F, Keogh A, Salas G, Prina-Mello A, Lacal JC, del Pozo A, Pankhurst Q, Hidalgo M, Gazeau F, Somoza A, Schwartz S Jr*, Abasolo I*. (*co-corresponding authors).
Preclinical development of magnetic nanoparticles for hyperthermia treatment of pancreatic cancer.
ACS Applied Materials & Interfaces, 2025 Jan 15;17(2):2924-2939
DOI: 10.1021/acsami.4c16129
IF: 10.38
Moreno A, Sandúa A, Ferrer-Costa R, Jacobs-Cacha C, Varo N, Ancizu-Marckert J, Robles JE, Pérez Gracia JL, Alegre E, González Á
The analytical impact of extracellular vesicles PSA on different commercial total PSA measurement methods.
Biochem Med (Zagreb). 2026 Feb 15;36(1):010703
DOI: 10.11613/BM.2026.010703.
IF: 3.8
Guerrero M, Marican A, Rafael D, Andrade F, Moore-Carrasco R, Vijayakumar S, Salinas P, Cabrera-Barjas G, Lara J, Durán-Lara EF.
On-demand dual-stimuli-responsive hydrogels for localized and sustained delivery of MP-L [I5R8] to treat bacterial wound infections.
Colloids Surf B Biointerfaces. 2025 Jul;251:114636.
DOI: 10.1016/j.colsurfb.2025.114636.
IF: 5.6
Piñeiro P, Langer J, Seras-Franzoso J, Jimenez de Aberasturi D, Abalde-Cela S, Henriksen-Lacey M, Liz-Marzán LM.
SERSµDrop: A Platform to Study Cell-Cell Communication via SERS Imaging.
Small. 2026 Jan;22(1):e08020.
DOI: 10.1002/smll.202508020.
IF: 12.1
SELECTED PROJECTS
A KEY TO THE RATIONAL DESIGN OF EXTRACELLULAR VESICLES-MIMICKING NANOPARTICLES (MIMIC-KeY)
Principal Investigator: Simo Schwartz Jr
Agency: European Commission – H2020-FETOPEN.
Funding: 457,250.00 €
Period: 2021-2025
Autonomous Scanning Probe Microscopy for Life Sciences and Medicine powered by Artificial Intelligence (SPM4.0)
Principal Investigator: Fernanda Raquel da Silva Andrade
Agency: European Commission – HORIZON-MSCA-2023-DN-01
Funding: 251,971.20 €
Period: 2024-2028
Patient-Centric blOod saMpling FOr impRoved healThcare (Project-COMFORT)
Principal Investigator: Simo Schwartz Jr
Agency: European Commission – HORIZON-JU-IHI-2023-04-two-stage
Funding: 288,262.5 €
Period: 2025-2029
Smart pathology slide scanner for diagnosis and patient-specific treatment recommendation in oncology (CancerScan). Ref: 101186829
Principal Investigator: Santiago Ramon y Cajal
Agency: European Commission – HORIZON-EIC-2024-PATHFINDEROPEN-01
Funding: 609,000 €
Period: 2025-2029
Impact of stem-related tumor extracellular vesicles subsets in TNBC progression.
Principal Investigator: Joaquim Seras Franzoso
Agency: Instituto de Salud Carlos III
Funding: 119,567 €
Period: 2024-2028
PATENTS
Biomarkers for bioimplants risk of bad response
Priority Number: PCT/EP2011/056393
Priority Date: 2010
Applicants: 100% VHIR (Simó Schwartz Navarro, Jaume Alijotas Reig)
Method for producing enzymes
Priority Number: 2194225 PCT application number: PCT/EP2013/063646
Priority Date: 28/06/2013
Applicants: Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBEREHD; Centro de Investigacion Biomedica en Red CIBER, Fundacio Institut de Recerca Hospital Universitari Vall dHebron (VHIR). Simón Schwartz Navarro, Ibane Abasolo Olaortua, Joaquim Seras Franzoso, Jose Luis Corchero Nieto
Cell Penetrating Peptides.
Priority Number: P5615EP00
Priority Date: 2020
Applicants: 100% VHIR (Simo Schwartz Navarro, Joan Sayós Ortega, Fernanda da Silva Andrade, Águeda Martínez Barriocanal, Diana Fernandes da Sousa, Joaquim Seras Franzoso)
Liposomes and its use for Enzyme Delivery
Priority Number: EP21382062.4 and US20240115502A1
Priority Date: 27/01/2021
Applicants: CSIC, VHIR, UAB, NANOMOL TECHNOLOGIES SL, LEANBIO SL
DISSEMINATION ACTIVITIES
European Researchers Night
Place: CosmoCaixa Museum,
Date: 26/09/2025
Brief: A research from our group was invited for a talk. Workshop: Misión Nanoagentes:
El Viaje de una Nanopartícula
European Researchers Night
Place: CosmoCaixa Museum
Date: 26/09/2025
Brief: Talk in Workshop: Explora La Ciencia De Los Hidrogeles. Materiales Que Curan.
GIMM Festival
Place: Lisbon at the Pavilhão Portugal
Date: 06/09/2025
Brief: Talk - Explore the Science of Hydrogels: Smart Materials for a healthier aging
International Rare Diseases Day
Place: Vall d'Hebron Research Institute
Date: 28/02/2025
Brief: Patients Visit to the Laboratory
International Day of Women and Girls in Science
Place: Vall d'Hebron Research Institute
Date: 11/02/2025
Brief: Students Visit to the Laboratory
